Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

22nd Century Group, Inc XXII

Consumer Defensive — Tobacco

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
1.33
Revenue
14.52
Net Income
(3.93)
Free Cash Flow
(9.52)
Net Debt
(5.61)
Current Ratio
2.61
Debt/Equity
0.02
P/E ratio
0.00
P/S ratio
0.03
P/B ratio
0.02
Past 5Y EPS Growth
52.01%
This Y EPS Growth
99.98%
Next Y EPS Growth
90.00%
Next 5Y EPS Growth
—
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 2.06 4.42 7.15 6.06
Receivables 1.67 1.70 3.59 3.58
Inventory 4.35 2.02 4.33 4.54
Other 3.77 0.77 — —
16.28 11.52 17.63 16.82
2023 2024 2025 Q'26
Payables 4.45 2.40 1.00 0.70
ST’ Debt 5.85 1.50 — —
Other 1.85 0.02 1.72 1.43
25.03 9.96 7.27 6.45
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 4.11 2.86 — —
—
’25 5.96 4.08 4.01 3.54
17.59
’24 6.47 7.95 5.95 4.02
24.38
’23 8.93 8.05 7.87 7.36
32.20
’22 9.05 14.48 19.38 (2.40)
40.50
’21 6.81 8.37 7.81 7.96
30.95
’20 7.06 6.44 7.31 7.31
28.11
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (3.10) (3.99) — —
—
’25 (2.98) (3.48) (4.02) 2.75
(7.72)
’24 (2.25) (4.71) (2.98) (4.40)
(14.34)
’23 (17.50) (19.83) (12.85) (4.80)
(54.99)
’22 (7.93) (11.82) (12.90) (19.07)
(51.71)
’21 (3.91) (8.36) (5.94) (4.63)
(22.84)
’20 (4.66) (6.81) (1.15) (3.00)
(15.62)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (3.15) (4.32) — —
—
’25 (3.03) (2.75) (4.04) 1.99
(7.83)
’24 (2.24) (4.78) (3.05) (4.42)
(14.48)
’23 (19.33) (20.91) (14.08) (6.00)
(60.32)
’22 (8.29) (12.89) (14.36) (20.19)
(55.73)
’21 (4.03) (8.81) (6.08) (4.99)
(23.91)
’20 (4.77) (6.94) (1.29) (3.14)
(16.14)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (361.60) (104.00) — —
—
’25 (17.23k) (4.08k) (83.96) —
(1.06k)
’24 (2.74m) (195.62k) (512.33k) —
(1.21m)
’23 (17.88m) (20.87m) (54.85m) (17.14m)
(108.50m)
’22 (11.17m) (13.41m) (13.41m) (26.81m)
(69.27m)
’21 (6.70m) (6.70m) (13.41m) (20.11m)
(46.92m)
’20 (6.70m) (8.94m) (6.70m) (11.17m)
(31.28m)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

2
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 183,319,200.00 2,414,448.00 26,910.00 224.10 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 699,742,784.00 282,803,392.00 4,014,765.00 86,181.00 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 198 64 56 32 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.20 0.50 0.44 0.55 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 40.50 32.20 24.38 17.59 ‡‡‡‡‡ — —
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.56% (27.00%) (9.84%) (17.84%) — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (36.53) (54.64) (15.46) (13.14) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (90.20%) (169.67%) (63.43%) (74.74%) ‡‡‡ — —
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (59.80) (140.77) (15.16) (5.05) ‡‡‡‡‡ — —
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.57 4.86 1.26 1.16 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.15 0.00 0.00 1,911.63 ‡‡‡‡‡ — —
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (69,269,030.00) (108,501,200.00) (1,199,194.00) (1,057.40) ‡‡‡‡ — —
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.02) 0.00 0.00 (839.46) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.31) 0.00 0.00 (11.41) ‡‡‡ — —
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.34) 0.00 0.00 (850.87) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.47 0.00 0.00 2,010.00 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.86 0.00 0.00 0.01 ‡‡‡‡‡ — —
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ — —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 64,647,630.62 0.00 0.00 0.12 ‡‡‡ — —
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 27,280,997.01 0.00 0.00 0.13 ‡‡‡ — —
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 64,647,630.23 0.37 0.09 (0.07) ‡‡‡‡ — —
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (46,978,391.50) (0.20) (0.15) 0.17 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (51.71) (54.99) (14.34) (7.72) ‡‡‡ — —
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.02) (5.33) (0.14) (0.10) — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (55.73) (60.32) (14.48) (7.83) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.59 (8.76) 1.56 10.36 — — —
Working Cap'
‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.59 13.91 6.67 0.50 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (15.81) 11.85 2.24 (6.64) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 95.98 (8.41) 4.01 18.49 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (62.75%) (212.12%) (103.57%) (39.97%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (26.22%) (816.81%) (139.39%) (61.02%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (73.81%) (344.35%) 1,158.12% (98.46%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

22nd Century Group (XXII) stands at an exhilarating inflection point in the disruptive world of plant-based biotech, pioneering low-nicotine tobacco via FDA-approved VLN cigarettes and venturing into high-potential hemp derivatives. After a decade of bold innovation—from explosive revenue growth peaking at $40.5 million in 2022 to navigating regulatory wins and pivots like the Qolo acquisition—the company has stabilized amid challenges like margin erosion and dilutions. Now, with slashed headcount boosting efficiency and forecasts signaling a dramatic rebound, XXII is poised for a revenue snapback to $32.5 million by 2026, alongside narrowing losses and positive EBT in 2025.

Financial turnaround signals are electric: gross margins improving from deep negatives, ROE flipping to +11.6%, and free cash flow projected at +$12.3 million next year with zero capex. The balance sheet shines with deleveraged debt, positive equity, and rock-bottom valuations—PS at 0.03x and PB at 0.18x—screaming undervaluation versus agritech peers. Analyst consensus screams 2000% upside, fueled by these metrics and insider neutrality amid restructuring.

Catalysts abound in emerging nicotine-reduction mandates and U.S. cannabis rescheduling, potentially reigniting the 300%+ surges of yesteryear. While execution risks linger, XXII’s high-beta profile offers speculative rocket fuel for growth seekers eyeing biotech’s next wave—don’t miss the full analysis for the upside details!

Read full commentary →

22nd Century Group, Inc (XXII) Latest News

News by impact score

Fine-tune

1 Sep

3 , 8:00 AM
22nd Century Group CEO Larry Firestone's mid-year stockholder letter reports improved gross margins, reach into roughly 5,000 retail outlets, and a market opportunity above $50 billion. Stockholder letter notes margin gains and retail expansion indicating moderate operational progress and market potential.

13 Aug

4 transcript , 7:09 PM
22nd Century Group Inc outlined a strategic shift during its Q2 2026 earnings call. Strategic shift signals major changes that could significantly alter company trajectory.

3 , 6:00 AM
22nd Century Group reported financial results for the second quarter of 2026. Quarterly results release supplies metrics that shape near-term valuation without guaranteeing structural change.

21 May

4 GlobeNewswire, 7:00 AM
22nd Century Group launches Pinnacle VLN reduced-nicotine cigarette trial in California, entering another major state market. California trial launch expands reduced-nicotine product reach into a key state and supports revenue and regulatory progress.

18 May

4 GlobeNewswire, 9:00 AM
22nd Century Group launches Pinnacle Pure expanding its high-margin Pinnacle Platform to major U.S. retailers. New product launch at major retailers expands distribution and revenue potential.

15 May

4 GlobeNewswire, 8:37 AM
22nd Century Group (Nasdaq: XXII) launches major VLN® retail expansion in Metro New York and Northern New Jersey under Pinnacle brand. Major retail expansion in high-population markets significantly boosts VLN® distribution, revenue potential, and competitive positioning.

12 May

4 GlobeNewswire, 1:50 PM
FDA has filed 22nd Century Group, Inc.'s applications to renew Modified Risk Tobacco Product (MRTP) orders for VLN® cigarettes and cigars for scientific review. FDA acceptance of VLN MRTP renewal applications advances regulatory approval for reduced-risk marketing claims, potentially driving significant revenue growth and market expansion.

8 May

4 app.moby.co, 8:30 AM
22nd Century Group, Inc. (XXII) released Q1 2026 earnings call summary covering financial results, operational updates, and strategic outlook. Q1 earnings call summary reveals key financial metrics and strategic shifts directly influencing XXII's performance and investor sentiment.

7 May

3 GlobeNewswire, 6:00 AM
22nd Century Group, Inc. (XXII) reported its first quarter 2026 financial results. Quarterly financial results directly influence financial performance and market sentiment for 22nd Century Group.

29 Apr

4 GlobeNewswire, 4:35 PM
22nd Century Group outlines 2026 vision emphasizing VLN® product expansion and leadership in tobacco harm reduction. 2026 vision for VLN growth and tobacco harm reduction leadership represents major strategic positioning with potential to boost market performance.

23 Apr

4 GlobeNewswire, 7:50 AM
22nd Century Group (XXII) expands its reduced nicotine platform through a new testing services agreement with North Carolina State University. University partnership bolsters core reduced nicotine platform expansion, enhancing innovation and competitive positioning.

7 Apr

4 GlobeNewswire, 8:00 AM
22nd Century Group advances 100mm VLN® reduced-nicotine cigarettes to target nearly half of the $82 billion U.S. cigarette market. Targeting half of $82B U.S. cigarette market with VLN® product represents major strategic expansion and revenue potential.

26 Mar

4 GuruFocus.com, 3:00 PM
22nd Century Group Inc (XXII) Q4 2025 earnings call highlights strategic shift fueling growth amid positive outlook. Strategic shift in Q4 2025 earnings call signals major moves to enhance XXII's trajectory and investor sentiment.

4 GlobeNewswire, 6:00 AM
22nd Century Group, Inc. (XXII) reported fourth quarter and full-year 2025 financial results. Releasing full-year financial results directly affects financial performance metrics, investor sentiment, and stock trajectory.

23 Feb

3 GlobeNewswireSimply Wall St., 5:07 PM
22nd Century Group reports sustained early sales momentum for VLN® reduced nicotine cigarette products across retail channels. Continued early sales growth for VLN products indicates moderate revenue uplift and improved market traction without transformative scale.

20 Feb

4 GlobeNewswire, 4:15 PM
22nd Century Group, Inc. (XXII) preliminarily reported fourth quarter and full year 2025 financial results. Preliminary financial results for Q4 and full year 2025 directly influence investor sentiment, stock price, and future performance expectations.

15 Jan

4 GlobeNewswire, 9:00 AM
Larry Firestone, CEO and Chairman of 22nd Century Group, Inc (XXII), provided a year-in-review letter to stockholders for 2025, highlighting the company's achievements, strategic initiatives, and future outlook. The letter emphasized advancements in product development, regulatory progress, and market positioning, aiming to reassure investors about the company's growth trajectory and commitment to innovation in the tobacco and hemp industries. The letter outlines significant strategic initiatives and advancements that could notably influence the company's future performance and investor sentiment.

6 Jan

4 GlobeNewswire, 6:10 AM
22nd Century Group, Inc. has filed for the renewal of its Modified Risk Tobacco Product (MRTP) designation for VLN®, the only combustible tobacco product authorized by the FDA to help smokers reduce their consumption. This renewal aims to reinforce the product's role in promoting reduced harm among smokers while maintaining compliance with regulatory standards. The MRTP renewal represents a significant regulatory milestone that could enhance market positioning and investor sentiment for 22nd Century Group.

26 Nov

3 Newsfile, 10:21 AM
Emerging Growth Research has released an update report for Q3 2025 on 22nd Century Group, Inc. (XXII), highlighting the company's recent developments and performance metrics. The report provides insights into the company's growth strategies and market positioning, reflecting on its potential for future expansion and innovation in the industry. The report indicates moderate influence on the company's financial performance and market positioning.

5 Nov

4 GuruFocus.com, 12:13 AM
22nd Century Group, Inc (XXII) reported its Q3 2025 earnings, highlighting strategic shifts aimed at enhancing financial performance. The company is focusing on innovation and market expansion, particularly in the reduced-risk tobacco and hemp sectors. Management emphasized the importance of regulatory compliance and adapting to market dynamics to drive growth. Financial results showed mixed performance, with some areas exceeding expectations while others faced challenges. The call outlined future initiatives and investments intended to strengthen the company's competitive position. Strategic shifts and market expansion efforts are expected to significantly influence the company's future trajectory and investor sentiment.

4 Nov

4 Associated Press Finance, 6:24 AM
22nd Century Group, Inc. reported its Q3 earnings, highlighting a significant increase in revenue driven by strong demand for its reduced nicotine tobacco products. The company continues to focus on its innovative plant biotechnology and aims to expand its market presence. Despite challenges in the broader market, 22nd Century remains optimistic about future growth opportunities and strategic partnerships. The increase in revenue and focus on innovative products indicate a significant impact on future performance and market positioning.

4 , 6:00 AM
22nd Century Group, Inc. reported its financial results for the third quarter of 2025, highlighting significant revenue growth and advancements in its product pipeline. The company continues to focus on its innovative tobacco and hemp products, aiming to capture a larger market share. Management expressed optimism about future prospects and ongoing strategic initiatives to enhance operational efficiency and expand distribution channels. Significant revenue growth and advancements in product offerings indicate a strong potential for future market performance.

28 Oct

3 GlobeNewswire, 5:07 PM
22nd Century Group, Inc. has received $9.5 million from the settlement of an insurance claim. This settlement is expected to bolster the company's financial position and support its ongoing operations and strategic initiatives. The insurance settlement provides a financial boost that may positively influence the company's operations and market sentiment.

23 Oct

4 GlobeNewswire, 7:45 AM
22nd Century Group, Inc. has launched its VLN® product in collaboration with a major convenience store chain, enhancing its market presence. The company has also introduced new marketing materials and is actively expanding state authorizations for its products, indicating a strategic push to increase distribution and brand visibility. The launch of VLN® with a major retailer and expansion of state authorizations are significant strategic moves that could enhance market positioning and investor sentiment.

30 Sep

4 GlobeNewswire, 9:05 AM
22nd Century Group, Inc. has submitted comments to the FDA supporting the proposed mandate for reduced nicotine content in cigarettes. The company advocates for this regulation as a means to reduce smoking rates and improve public health. 22nd Century emphasizes its commitment to developing reduced nicotine products and believes that the mandate aligns with its mission to provide innovative solutions for tobacco harm reduction. The FDA's proposed mandate for reduced nicotine content could significantly influence 22nd Century's strategic direction and market positioning.

24 Sep

3 GlobeNewswire, 4:45 PM
22nd Century Group, Inc. has secured $9.5 million in cash proceeds from the settlement of an insurance claim. This settlement is expected to enhance the company's financial position and support its ongoing operations and strategic initiatives. The settlement provides a notable cash influx that may positively influence financial performance but does not fundamentally change the company's trajectory.

18 Sep

4 GlobeNewswire, 4:15 PM
22nd Century Group, Inc. announced that it has achieved a debt-free balance sheet, positioning the company for future growth. The elimination of debt allows for increased flexibility in pursuing strategic initiatives and capitalizing on new opportunities. Additionally, the company has secured new growth capital to support its expansion efforts. Achieving a debt-free status and securing new growth capital are significant strategic moves that can enhance the company's financial stability and growth potential.

5 Sep

3 GlobeNewswire, 5:37 PM
22nd Century Group, Inc. will participate in the HC Wainwright Conference in New York City on September 9, 2025. The event is expected to provide a platform for the company to engage with investors and discuss its strategic initiatives and growth prospects. Participation in investor conferences can moderately influence market sentiment and provide opportunities for strategic engagement.

22 Aug

3 , 3:17 PM
Emerging Growth Research has released an update report for Q2 2025 on 22nd Century Group, Inc (XXII), highlighting the company's recent developments and performance metrics. The report provides insights into the company's growth strategies, financial results, and market positioning, indicating a positive outlook for future operations. The report outlines key developments that may moderately influence the company's financial performance and market positioning.

20 Aug

4 GlobeNewswire, 7:00 AM
Larry Firestone, CEO and Chairman of 22nd Century Group, Inc (XXII), provided a technology and regulatory update to stockholders, highlighting advancements in the company's proprietary technology and ongoing regulatory efforts. The letter outlines the company's strategic direction and emphasizes its commitment to innovation in the tobacco and hemp industries, aiming to enhance shareholder value and market position. Significant advancements in technology and regulatory efforts are likely to impact the company's future performance and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us